Therapeutic approaches for prion disorders (Q36901944)

17 August 2017

1 reference

title

Therapeutic approaches for prion disorders (English)

1 reference

17 August 2017

0 references

Heike Ludewigs

1

1 reference

17 August 2017

Chantal Zuber

2

1 reference

17 August 2017

Karen Vana

3

1 reference

17 August 2017

Daphne Nikles

4

1 reference

17 August 2017

Inga Zerr

5

1 reference

17 August 2017

Stefan Weiss

6

1 reference

17 August 2017

publication date

1 August 2007

1 reference

Expert Review of Anti-infective Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

5

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

613-630

1 reference

Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

A new variant of Creutzfeldt-Jakob disease in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

A novel generation of heparan sulfate mimetics for the treatment of prion diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Polymerization of murine recombinant prion protein in nucleic acid solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Potent inhibition of scrapie-associated PrP accumulation by congo red

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

The anti-prion activity of Congo red. Putative mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Amphotericin B binds to amyloid fibrils and delays their formation: a therapeutic mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Tetracyclines affect prion infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Porphyrin and phthalocyanine antiscrapie compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Prophylactic and therapeutic effects of phthalocyanine tetrasulfonate in scrapie-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

A porphyrin increases survival time of mice after intracerebral prion infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Elimination of prions by branched polyamines and implications for therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

RNA molecules stimulate prion protein conversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Formation of native prions from minimal components in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Effectiveness of anthracycline against experimental prion disease in Syrian hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Evaluation of quinacrine treatment for prion diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Prion-protein-specific aptamer reduces PrPSc formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Prion (PrPSc)-specific epitope defined by a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrPSc replication in infected cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Bovine prion is endocytosed by human enterocytes via the 37 kDa/67 kDa laminin receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

A prion protein epitope selective for the pathologically misfolded conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Antibodies inhibit prion propagation and clear cell cultures of prion infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Clearance and prevention of prion infection in cell culture by anti-PrP antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Novel single chain antibodies to the prion protein identified by phage display

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Prion protein-specific antibodies for therapeutic intervention of transmissible spongiform encephalopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Mucosal vaccination delays or prevents prion infection via an oral route.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Infectious prions in the saliva and blood of deer with chronic wasting disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Inhibition of scrapie-associated PrP accumulation. Probing the role of glycosaminoglycans in amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Dominant-negative inhibition of prion replication in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Intracerebroventricular delivery of dominant negative prion protein in a mouse model of iatrogenic Creutzfeldt-Jakob disease after dura graft transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Mice devoid of PrP are resistant to scrapie

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

A trans-dominant negative 37kDa/67kDa laminin receptor mutant impairs PrP(Sc) propagation in scrapie-infected neuronal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Specific inhibition of pathological prion protein accumulation by small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Suppression of prion protein in livestock by RNA interference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Production of cattle lacking prion protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Knock-down of the 37-kDa/67-kDa laminin receptor in mouse brain by transgenic expression of specific antisense LRP RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Therapeutic approaches targeting the prion receptor LRP/LR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

A systematic review of prion therapeutics in experimental models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Effects of the polyene antibiotic derivative MS-8209 on the astrocyte lysosomal system of scrapie-infected hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Anti-amyloidogenic activity of tetracyclines: studies in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Early cognitive decline in Creutzfeldt-Jakob disease associated with human growth hormone treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

The neuropsychology of variant CJD: a comparative study with inherited and sporadic forms of prion disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Clinical diagnosis and differential diagnosis of CJD and vCJD. With special emphasis on laboratory tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Akinetic mutism as a classification criterion for the diagnosis of Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

How to improve the clinical diagnosis of Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Clinical course in young patients with sporadic Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Neurocognitive differential diagnosis of dementing diseases: Alzheimer's Dementia, Vascular Dementia, Frontotemporal Dementia, and Major Depressive Disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

NMR structure of the mouse prion protein domain PrP(121-231)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Branched polyamines cure prion-infected neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

PrPSc binding antibodies are potent inhibitors of prion replication in cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Jakob-Creutzfeldt disease: treatment by amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Short report: Creutzfeldt-Jakob disease treated with amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Creutzfeldt-Jakob disease treated with amantidine: A report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Failure of interferon to modify Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Results of quinacrine administration to patients with Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Cationic Lipopolyamines Induce Degradation of PrPSc in Scrapie-Infected Mouse Neuroblastoma Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

Monoclonal antibodies inhibit prion replication and delay the development of prion disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.613

21 January 2018

Identifiers

DOI

10.1586/14787210.5.4.613

1 reference

17 August 2017

1 reference